Molecularly targeted therapy in breast cancer: the new generation.
Breast cancer management has become increasingly complex, requiring the integration of data not only from the patient's history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb) and SUNITINIB (SU11248; Sutent) are discussed. This review article also includes relevant patents.
Nahleh
Zeina A
ZA
Division of Hematology-Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48201, USA. nahlehz@karmanos.org
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D015195:Drug Design; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors; D000077210:Sunitinib
D000970:Antineoplastic Agents; C490918:ESRRB protein, human; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011799:Quinazolines; D011960:Receptors, Estrogen; D000077341:Lapatinib; D000077210:Sunitinib